display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
es-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HER2 positive - 1st Line (L1)
trastuzumab based treatment
trastuzumab plus endocrine therapy SYSUCC-002
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel GeparQuinto

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons